Reaction
Magnetic Resonance Imaging Abnormal reporting signals
As of the last recalculation, Magnetic Resonance Imaging Abnormal appears in 1,162 FAERS reports alongside 22 co-occurring drug terms. The strongest observed disproportionality signal is OCRELIZUMAB (PRR 82.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ocrelizumab | 230 | 82.6 | 82.9 |
| Diroximel Fumarate | 26 | 40.0 | 40.0 |
| Alemtuzumab | 35 | 33.4 | 33.4 |
| Vigabatrin | 24 | 30.1 | 30.1 |
| Peginterferon Beta-1A | 18 | 25.0 | 25.0 |
| Glatiramer Acetate | 76 | 24.3 | 24.3 |
| Cladribine | 12 | 22.6 | 22.6 |
| Dimenhydrinate | 13 | 22.1 | 22.1 |
| Dimethyl Fumarate | 122 | 19.7 | 19.8 |
| Ofatumumab | 34 | 18.8 | 18.9 |
| Teriflunomide | 36 | 14.7 | 14.7 |
| Siponimod | 7 | 14.1 | 14.1 |
| Dalfampridine | 38 | 9.8 | 9.8 |
| Niraparib | 12 | 9.8 | 9.8 |
| Interferon Beta-1A | 93 | 9.3 | 9.3 |
| Fosaprepitant Dimeglumine | 7 | 9.2 | 9.2 |
| Rimegepant Sulfate | 6 | 8.5 | 8.5 |
| Natalizumab | 80 | 8.4 | 8.4 |
| Pemetrexed Disodium | 16 | 7.6 | 7.6 |
| Fingolimod Hcl | 35 | 7.4 | 7.4 |
| Asfotase Alfa | 4 | 7.2 | 7.2 |
| Interferon Beta-1B | 7 | 6.6 | 6.6 |